We are live on ! Find out more
SPA

Sherbrooke Park Advisers Portfolio holdings

AUM $38.7M
1-Year Est. Return 5.29%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
-5.29%
3 Year Est. Return
-9.59%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$514M
AUM Growth
+$301M
Cap. Flow
+$293M
Cap. Flow %
57.02%
Top 10 Hldgs %
5.45%
Holding
1,025
New
585
Increased
167
Reduced
66
Closed
207

Top Buys

Rank Stock Value
1
SSRM icon
SSR Mining
SSRM
+$4.08M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$3.92M
3
SMAR
Smartsheet Inc.
SMAR
+$2.98M
4
LEN icon
Lennar Class A
LEN
+$2.74M
5
DOW icon
Dow Inc
DOW
+$2.55M

Top Sells

Rank Stock Value
1
PG icon
Procter & Gamble
PG
+$2.12M
2
HOLX
Hologic
HOLX
+$2.01M
3
MPC icon
Marathon Petroleum
MPC
+$1.66M
4
KO icon
Coca-Cola
KO
+$1.58M
5
JBL icon
Jabil
JBL
+$1.45M

Sector Composition

Rank Sector Weight
1 Technology 22.07%
2 Industrials 18.09%
3 Consumer Discretionary 13.93%
4 Healthcare 10.29%
5 Financials 9.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDF icon
801
Cardiff Oncology
CRDF
$77.2M
$86.2K 0.02%
+16,148
New +$42.9K
PETS icon
802
PetMed Express
PETS
$42.3M
$85.5K 0.02%
17,843
-8,205
-31% -$47.7K
SLRN
803
DELISTED
ACELYRIN
SLRN
$80.4K 0.02%
+11,915
New +$90.5K
TTI icon
804
TETRA Technologies
TTI
$1.26B
$79.9K 0.02%
+18,036
New +$74.9K
MBI icon
805
MBIA
MBI
$260M
$79.5K 0.02%
11,760
-19,300
-62% -$122K
REAL icon
806
The RealReal
REAL
$1.5B
$78.9K 0.02%
+20,178
New +$48.1K
EVC icon
807
Entravision Communication
EVC
$1.1B
$77.8K 0.02%
+47,449
New +$157K
ACTG icon
808
Acacia Research
ACTG
$470M
$76.8K 0.01%
+14,409
New +$60.1K
AKYA
809
DELISTED
Akoya BioSciences
AKYA
$74.9K 0.01%
+15,960
New +$82.9K
CATO icon
810
Cato Corp
CATO
$66.1M
$72.9K 0.01%
+12,627
New +$84.3K
SCPH
811
DELISTED
scPharmaceuticals
SCPH
$72.4K 0.01%
+14,422
New +$80.8K
HLLY icon
812
Holley
HLLY
$384M
$65.4K 0.01%
+14,659
New +$66.9K
TSVT
813
DELISTED
2seventy bio
TSVT
$64.1K 0.01%
11,976
-16,246
-58% -$76.4K
TSE
814
DELISTED
Trinseo
TSE
$63K 0.01%
+16,663
New +$88.9K
SGHT icon
815
Sight Sciences
SGHT
$412M
$62.6K 0.01%
+11,851
New +$55.7K
BDTX icon
816
Black Diamond Therapeutics
BDTX
$112M
$55.3K 0.01%
+10,912
New +$44K
DLTH icon
817
Duluth Holdings
DLTH
$159M
$54.7K 0.01%
+11,166
New +$54.5K
PRCH icon
818
Porch Group
PRCH
$1.8B
$48.7K 0.01%
+11,291
New +$33.7K
ABNB icon
819
Airbnb
ABNB
$107B
– –
-4,311
Closed -$587K
ACCO icon
820
Acco Brands
ACCO
$407M
– –
-11,665
Closed -$70.9K
AGCO icon
821
AGCO
AGCO
$7.2B
– –
-4,036
Closed -$490K
AL
822
DELISTED
Air Lease Corp
AL
– –
-6,551
Closed -$275K
ALLY icon
823
Ally Financial
ALLY
$13.3B
– –
-6,882
Closed -$240K
AMC icon
824
AMC Entertainment Holdings
AMC
$2.31B
– –
-19,857
Closed -$122K
AMTX icon
825
Aemetis
AMTX
$124M
– –
-13,503
Closed -$70.8K
31 32
33
34 35

Similar funds

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 13.88% 1-Year Est. Return
ISSM
Invesco Senior Secured Management New York $40.9M AUM 3.88% 1-Year Est. Return
KCM
Kawa Capital Management Hallandale Beach, Florida $43.2M AUM 13.52% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
APM
Advanced Portfolio Management New York $32.8M AUM 6.64% 1-Year Est. Return
CI
Centerstone Investors New York $31.8M AUM 32.46% 1-Year Est. Return

Sherbrooke Park Advisers's Q1 2024 Portfolio in Review

As of Q1 2024, Sherbrooke Park Advisers held 1,025 positions worth $514M, up 141% from $213M the previous quarter. Its ten largest holdings account for 5.5% of the portfolio.

Sherbrooke Park Advisers deployed $293M of net new capital in Q1 2024, opening 585 new positions and adding to 167 existing holdings. Its largest new stake was Amylyx Pharmaceuticals: 299,452 shares worth $850K.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 20% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Procter & Gamble, an estimated $2.12M trimmed.

  • Sherbrooke Park Advisers's largest Q1 2024 buy was Amylyx Pharmaceuticals: 299,452 shares worth $850K.
  • Sherbrooke Park Advisers added most to SSR Mining in Q1 2024, an estimated $4.08M increase.
  • Sherbrooke Park Advisers's biggest Q1 2024 reduction was Procter & Gamble, cutting an estimated $2.12M.
  • Sherbrooke Park Advisers fully exited Hologic in Q1 2024, selling an estimated $2.01M.
  • Sherbrooke Park Advisers's ten largest holdings make up 5.5% of its $514M portfolio in Q1 2024.
  • Sherbrooke Park Advisers opened 585 new positions and closed 207 in Q1 2024.
  • Sherbrooke Park Advisers's portfolio value rose 141% quarter-over-quarter to $514M.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2024, filed 15 May 2024.